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ABSTRACT
Carbapenem-hydrolysing oxacillinases are reported increasingly in Acinetobacter baumannii. This study
investigated the role of these b-lactamases in causing resistance to carbapenems in 83 epidemiologically
related and unrelated imipenem-resistant A. baumannii clinical isolates. The isolates were also analysed
for the presence of ISAba1 in the promoter region of the blaOXA-51-like gene in order to investigate the role
of ISAba1 in OXA-51 expression. All clinical isolates contained a blaOXA-51-like gene, 20% contained a
blaOXA-58-like gene, and 42% contained a blaOXA-40-like gene; blaOXA-23-like, blaIMP and blaVIM genes were
not detected in any of the isolates investigated. ISAba1 was found in 24 (82.7%) of 28 pulsetypes, and
was located in the promoter region of the blaOXA-51-like gene in ﬁve (20.8%) of these pulsetypes.
Expression of blaOXA-51 was detected in the ﬁve isolates with ISAba1 located in the promoter region, but
was not detected in an isogenic imipenem-susceptible A. baumannii isolate that did not have ISAba1
located in the promoter region. It was concluded that there is a high prevalence of oxacillinases with
activity against carbapenems among genetically unrelated A. baumannii clinical isolates from Spain, and
that concomitant expression of two carbapenemases (OXA-51-like and either OXA-40-like or OXA-58-
like) may take place. Insertion of an ISAba1-like element in the promoter of the blaOXA-51-like gene
promotes the expression of this gene, although this did not seem to play a major role in carbapenem
resistance.
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INTRODUCTION
Acinetobacter baumannii is a nosocomial pathogen
that is recognised as being responsible for a
wide spectrum of infections, including bacter-
aemia, secondary meningitis, pneumonia and
urinary tract infections [1]. It has been impli-
cated increasingly in hospital-acquired infec-
tions, mostly affecting debilitated patients in
intensive care units, in whom such infections
are associated with high mortality rates [1].
Administration of appropriate antimicrobial
therapy to these patients is therefore essential.
Carbapenems usually have good potency
against A. baumannii, with imipenem being the
most active agent [1], but carbapenem resistance
in A. baumannii has increasingly been reported
worldwide during the last decade [2,3]. Several
mechanisms responsible for resistance to carba-
penems in A. baumannii have been described:
(i) synthesis of carbapenemases [2]; (ii) decreased
outer-membrane permeability caused by the loss
or reduced expression of porins [4–8]; and
(iii) alterations in penicillin-bindingproteins [9,10].
Although IMP-type [11–14] and VIM-type
[15] carbapenemases have been reported in
A. baumannii, the carbapenemases found most
frequently are those belonging to class D.
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To date, four groups of carbapenem-hydrolysing
oxacillinases (Ambler class D b-lactamases) have
been described in A. baumannii [16–20]. The ﬁrst
oxacillinase described in A. baumannii with
activity against carbapenems was OXA-23 [21],
and this enzyme is in a group that currently
includes OXA-23, OXA-27 and OXA-49 [17,22].
A second group comprises OXA-24, OXA-25,
OXA-26 and OXA-40 [16,22,23], and shares 60%
amino-acid identity with the ﬁrst group. The
third and largest group comprises the OXA-51-
like carbapenemases, which are encoded by
chromosomally located genes that show 56%
and <63% amino-acid identity with groups 1
and 2, respectively [24,25]. Finally, a new
carbapenemase (OXA-58) has been characterised
that shares <50% amino-acid identity with the
other three groups.
Recently, a novel insertion sequence (IS), ISAba1
(www-is.biotoul.fr ⁄ is.html), which has 11-bp
inverted repeat sequences ﬂanked by 9-bp
direct repeats of the target sequence, was
identiﬁed in A. baumannii [26]. Many IS ele-
ments contain promoters that play a role in the
expression of antibiotic resistance genes situated
downstream from the site of insertion [27,28].
ISAba1 has been identiﬁed adjacent to a
b-lactamase resistance gene (ampC) inA. baumannii
[26,29], and primer extension studies showed
that transcription of the ampC gene was dependent
on promoter sequences within ISAba1 [27].
ISAba1 has also been found upstream from
blaOXA-51-like and, probably, blaOXA-23-like genes
[30,31].
The aim of the present study was to investigate
the distribution of the different OXA-type
enzymes, as well as VIM and IMP enzymes, in
a collection of A. baumannii isolates from various
locations in Spain. The presence of ISAba1 up-
stream of blaOXA-51-like genes, together with its
role in the expression of these genes, was also
investigated.
MATERIALS AND METHODS
Bacterial isolates
Eighty-three isolates were selected from among 221 clinical
isolates collected during November 2000 from 25 Spanish
hospitals as part of a previous study of carbapenem resistance.
All isolates were identiﬁed by ampliﬁed rDNA restriction
analysis [32], and their epidemiological relationships were
determined by pulsed-ﬁeld gel electrophoresis, according to
the method of Gautom [33].
Susceptibility testing
Microdilution assays according to CLSI guidelines [34] were
used to determine MICs of the following antimicrobial agents:
ampicillin, piperacillin, cephalothin, cefoxitin, gentamicin,
amikacin, tobramycin, tetracycline, minocycline, doxycycline,
rifampicin and colistin (Sigma, Madrid, Spain), ceftazidime
(GlaxoSmithKline, Uxbridge, UK), cefepime (Bristol-Myers
Squibb, Madrid, Spain), sulbactam and azithromycin (Pﬁzer,
Sandwich, UK), imipenem (Merck, Hoddesdon, UK), merope-
nem (AstraZeneca, Macclesﬁeld, UK), ciproﬂoxacin (Bayer,
Leverkusen, Germany), and co-trimoxazole (Galloso, Madrid,
Spain) [35]. Breakpoints used were those recommended by the
CLSI for non-fermentative Gram-negative bacilli [34]; control
strains used were those described previously [35].
PCR analysis
DNA was extracted by boiling a single colony in 25 lL of
water for 10 min and then centrifuging in a microcentrifuge at
maximum speed for 1 min. This was followed by the addition
of 25 lL of a reaction mixture containing 0.5 lM of the
relevant primers (Table 1), 200 lM dNTPs and 2.5 U of Taq
DNA polymerase, to give a ﬁnal volume of 50 lL. Initial
Table 1. Primers used in this study
Primers Genes detected Sequence (5’ ﬁ 3’) Product size (bp) Annealing temp.
OXA51 U oxa51, oxa69, oxa71, oxa75, oxa 78 AACAAGCGCTATTTTTATTTCAG 641 53C
OXA51 L CCCATCCCCAACCACTTTT
OXA58 U oxa58 AGTATTGGGGCTTGTGCT 453 50C
OXA58 L AACTTCCGTGCCTATTTG
OXA24 U oxa24, oxa25, oxa26, oxa33, oxa40, oxa72 ATGAAAAAATTTATACTTCCTATATTCAGC 825 50C
OXA24 L TTAAATGATTCCAAGATTTTCTAGC
OXA23 U oxa23, oxa27, oxa49 GATGTGTCATAGTATTCGTCGT 641 52C
OXA23 L TCACAACAACTAAAAGCACTGT
ISaba1U ISAba1 CATTGGCATTAAACTGAGGAGAAA 451 53C
ISaba1L TTGGAAATGGGGAAAACGAA
VIM U VIM-type ATTGGTCTATTTGACCGCGTC 780 55C
VIM L TGCTACTCAACGACTGCGCG
IMP U IMP-type CATGGTTTGGTGGTTCTTGT 488 55C
IMP L ATAATTTGGCGGACTTTGGC
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denaturation (95C for 5 min) was followed by 30 cycles of
95C for 1 min, the optimal annealing temperature for each
gene (Table 1) for 1 min, and 72C for 1 min, with a ﬁnal
extension step at 72C for 10 min. PCR products were resolved
in agarose 2% w ⁄v gels in TBE buffer (89 mM Tris base,
89 mM boric acid, 2 mM EDTA). Gels were stained with
ethidium bromide and the DNA was visualised by UV light
transillumination at 302 nm. When required, PCR products
were recovered directly from the agarose gels and were
puriﬁed with the Wizard SV gel and PCR system (Promega,
Madison, WI, USA) according to the manufacturer’s instruc-
tions. DNA sequencing was performed using a BigDye
Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems,
Warrington, UK) and an automated DNA sequencer 3100
Genetic Analyzer (Applied Biosystems).
Quantiﬁcation of mRNA by RT-PCR
Onemilliliter of bacterial culture (OD600 0.6) was added rapidly
to a solution comprising 125 lL of ethanol 95% v ⁄v plus phenol
5% v ⁄v, andwas then centrifuged. The pellet was resuspended
in 100 lL of lysozyme solution in water (0.1 mg ⁄mL),
vortexed, and then incubated for 30 min at room temperature,
after which mRNA was extracted and puriﬁed using an
RNAwiz kit (Ambion, Austin, TX, USA). RT-PCR was then
performed using a SuperScrip One-step RT-PCR Kit with
Platinum Taq (Invitrogen, Barcelona, Spain). Two sets of
primers, OXA51 U and OXA51 L (Table 1), were used for the
blaOXA-51-like gene, with primers for the 16S rRNA gene as an
internal control. Reaction mixtures comprised 1· reaction mix
(SuperScrip One-step RT-PCR Kit), 0.5 lM each primer, 1 U of
RT ⁄platinum Taq MIX (SuperScrip One-step RT-PCR Kit),
500 ng of RNA template, and distilled water to 50 lL. Each
reaction was performed with two initial steps, the ﬁrst at 50C
for 30 min (reverse transcription), and the second at 95C for
2 min to activate the Taq polymerase, followed by 19 cycles of
95C for 1 min, 53C for 1 min and 72C for 1 min.
For quantiﬁcation, it is important to stop the reaction,
usually between cycles 10 and 25, to compare the expression of a
gene in different isolates. After several trials, 19 cycles were
used for each of the two genes. This low cycle number produces
amplicons that are difﬁcult to see in an agarose gel stained with
ethidium bromide; the RT-PCR products obtained were there-
fore analysed in acrylamide gels (Amersham Biosciences,
Barcelona, Spain) using a GenePhor apparatus (Pharmacia
Biotech, Barcelona, Spain). The gel was then stained using a
DNA silver-staining kit (Amersham Biosciences).
RESULTS
In total, 221 A. baumannii clinical isolates were
collected from 25 Spanish hospitals [35]. All 83
imipenem-resistant A. baumannii isolates from
this collection were chosen for the present study.
The 83 selected isolates belonged to 28 different
pulsetypes from 12 different hospitals. The num-
ber of isolates in each pulsetype ranged fromone to
18. Table 2 summarises the presence of the genes
encoding the main carbapenemases described to
Table 2. Distribution of different carbapenemase-encoding genes among isolates of Acinetobacter baumannii from various
locations in Spain
Hospital City
No. of
isolates
Pulsetype P
designation
Genes detected
Imipenem
MIC (mg ⁄L)OXA-51-like OXA-58-like OXA-40-like ISAba1 IS-OXA-51-likea
H. Bellvitge BCN 28 71 4 0 0 4 0 128
72 18 0 1 2 0 64–128
73 2 0 0 0 0 64
74 1 0 0 0 0 64
75 1 0 0 1 0 128
78 1 0 0 1 0 128
79 1 0 1 1 0 128
H. 12 Octubre MD 4 44 4 0 4 4 0 64–128
H. C. Salamanca SLM 1 11 1 0 0 0 0 64
H. La Princesa MD 2 41 2 0 2 2 0 128
H. M. Valdecilla SAN 2 32 2 2 0 2 0 16
H. Paraple´jicos TO 3 15 1 0 1 1 0 128
22 2 0 2 2 0 128
H. Reina Soﬁa CO 6 47 3 3 0 3 0 16–64
48 3 2 0 3 0 32–64
H. Vall d’Hebron BCN 1 45 1 0 0 1 1 128
H. V. Salud TO 6 50 5 0 5 5 0 128
52 1 0 1 1 0 128
H. V. Nieves GR 7 53 6 5 0 6 5 16–32
54 1 0 0 1 1 16
H. V. Rocio SE 20 56 9 0 9 9 0 128
57 2 0 2 2 0 128
59 2 0 2 2 0 128
61 3 3 0 3 3 16–32
61.2 3 0 3 3 0 128
65 1 1 0 0 0 16
H. Getafe MD 3 34 2 0 2 2 0 128
35 1 0 0 1 1 128
Total 83 28 83 16 35 62 11
% 100 19.3 42.2 74.7 13.3
City: BCN, Barcelona; MD, Madrid; SLM, Salamanca; SAN, Santander; TO, Toledo; CO, Co´rdoba; GR, Granada; SE, Sevilla.
P, number assigned to each pulsetype.
IS-OXA-51-like, isolates that contain ISAba1 inserted in the promoter region of the blaOXA-51-like gene.
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date in A. baumannii, including the four sub-
groups of oxacillinases having carbapenemase
activity, as well as IMP- and VIM-type enzymes.
All the isolates carried a gene encoding a
b-lactamase belonging to the OXA-51-like group.
In addition, 19% and 42% of the isolates carried a
gene encoding an OXA-58-like or an OXA-40-like
enzyme, respectively. The MICs of imipenem for
isolates carrying an OXA-40-like or an OXA-58-
like carbapenemase were ‡128 mg ⁄L and
16–64 mg ⁄L, respectively. No genes encoding
b-lactamases of the OXA-23-like group, or VIM
or IMP metallo-b-lactamases, were detected.
Sixty-two (74.7%) of the 83 isolates contained
the insertion sequence ISAba1, which was located
in the promoter region of the blaOXA-51-like gene
for 11 (17.7%) of the 62 isolates carrying this
insertion element. Some degree of heterogeneity
was observed within groups of isolates; thus,
pulsetype 72 contained 18 isolates, but only one
carried a blaOXA-40-like gene, and pulsetype 53
contained six isolates, ﬁve of which carried a
blaOXA-58-like gene, with four of these overex-
pressing a blaOXA-51-like gene, while the remain-
ing isolate did not carry a blaOXA-58-like gene and
overexpressed a blaOXA-51-like gene.
Expression of the blaOXA-51-like gene was inves-
tigated in ﬁve isolates belonging to pulsetypes 35,
45, 53, 54 and 61, respectively, in which ISAba1
was located in the promoter region of the
blaOXA-51-like gene. In isolates from three pulse-
types (35, 45 and 54), the blaOXA-51-like gene was
the only carbapenemase, whereas the remaining
two isolates (pulsetypes 53 and 61) also carried a
blaOXA-58-like carbapenemase. In addition, an
isolate belonging to pulsetype 53, which also
carried ISAba1, but not in the promoter region of
the blaOXA-51-like gene, was included as a control.
Fig. 1 shows that the blaOXA-51-like gene was
clearly expressed in all ﬁve isolates with ISAba1
in the promoter region of the gene (lanes 2–6), but
not in the control isolate (lane 1). The PCR
product obtained from the ampliﬁcation was
veriﬁed by sequencing using the ISAba1 forward
primer and the blaOXA-51-like gene reverse primer.
DISCUSSION
A. baumannii is associated frequently with noso-
comial infections, with imipenem being the most
active antimicrobial agent against these micro-
organisms. Acquisition of imipenem resistance
means that colistin, and perhaps tigecycline,
may be the only remaining therapeutic options
for treating infections caused by multiresistant
A. baumannii. The high level of resistance to
imipenem in A. baumannii clinical isolates and
the clinical risk-factors favouring the acquisition
of imipenem-resistant A. baumannii have been
reported previously [36]. Although carbapenem
resistance may be caused, in part, by impaired
permeability, resulting from decreased expression
of porins, or bymodiﬁcations in penicillin-binding
proteins [4–10], most recent reports have indi-
cated that carbapenem-hydrolysing b-lactamases
play a more signiﬁcant role [2]. In the present
study, all isolates produced an OXA-51-like
b-lactamase, with those that also produced an
OXA-40-likeb-lactamase having a higher imipenem
MIC than isolates that also produced an
OXA-58-like enzyme (Table 2). Other mecha-
nisms of resistance to imipenem may be present,
possibly including over-expression of the adeABC
efﬂux pump [37].
Da Silva et al. [38] showed that a multiresistant
epidemic clone of A. baumannii carrying the
blaOXA-40 gene was disseminated widely in Por-
tugal and Spain. In the present study, epidemio-
logically unrelated A. baumannii clinical isolates
carrying blaOXA-40-like genes were more prevalent
than isolates carrying blaOXA-58-like genes, sug-
gesting that dissemination of a genetic element
carrying a blaOXA-40-like gene may have taken
place. However, the spread of an A. baumannii
clone or a genetic element carrying this gene
M  1  2  3  4  5  6      M  7  8   9 10 11 12   M
blaOXA-51  16S rRNA 
798 bp641 bp
1500 bp 
1000 bp 
400 bp 
300 bp 
200 bp 
Fig. 1. Expression of blaOXA-51-like genes (lanes 1–6) and,
as controls, 16S rRNA genes (lanes 7–12). Lanes 1–6 and
7–12 show isolates belonging to pulsetypes 53, 35, 45, 53, 54
and 61, in that order. Lanes 1 and 7 contain an isolate
belonging to pulsetype 53 that carries ISAba1, but not in
the promoter region of the blaOXA-51-like gene. All other
lanes contain isolates with ISAba1 located in the promoter
region of the blaOXA-51-like gene.
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seems, at present, to be limited to Spain and
Portugal [38].
The OXA-58 carbapenemase described by Poi-
rel et al. [20] shares <50% amino-acid homology
with the three remaining OXA groups. OXA-58
was described originally in a carbapenem-resis-
tant isolate of A. baumannii from France, but this
carbapenemase has been found subsequently in
isolates from Austria, Greece, Romania, Spain,
Turkey and the UK [39–42], Argentina and
Kuwait [39], and Venezuela (E. Salazar, personal
communication). In the present study, an
OXA-58-like enzyme was found in six of 28
A. baumannii clinical isolates belonging to differ-
ent pulsetypes, again suggesting that a genetic
element carrying a blaOXA-58-like element may be
disseminating.
The heterogeneity among the OXA-51-like
group of enzymes is probably very high [24,41],
and it is known that the OXA-51-like enzymes are
intrinsic chromosomally-located b-lactamases in
A. baumannii [43]. In the present study, eight PCR
products from the ampliﬁed region of the
blaOXA-51-like gene were randomly chosen and
sequenced, and were found to show 100%
homology with either the blaOXA-66 ⁄ 76 gene (PCR
products from six different isolates) [25], the
blaOXA-71 gene (one isolate) [25], or the blaOXA-51
gene (one isolate) [24]. He´ritier et al. [43] showed
that OXA-69, which is closely related to OXA-51,
had only very weak catalytic efﬁciency for most
b-lactam antibiotics, including carbapenems, and
suggested that OXA-69 may not play a signiﬁcant
role in resistance to b-lactam antibiotics. The
present study demonstrated over-expression
of the blaOXA-51-like gene in all isolates with
ISAba1 located in the promoter region of the
blaOXA-51-like gene. Although another mechanism
of resistance to carbapenems cannot be ruled out,
the differing expression of the blaOXA-51-like gene
observed in the isogenic sensitive and resistant
isolates belonging to pulsetype 53 suggests that
insertion of ISAba1 in the promoter region of the
blaOXA-51-like gene may produce a slight increase
in the MIC of imipenem. The end of the ISAba1
element found inserted in the promoter region of
the blaOXA-51 gene was located seven bases from
the start codon of the blaOXA-51-like gene, as
described previously by Turton et al. [31].
In conclusion, although additional mechanisms
of resistance to carbapenems cannot be ruled out,
the present study demonstrated a high prevalence
of oxacillinases with activity against carbapenems
in genetically unrelated A. baumannii clinical iso-
lates from Spain, and conﬁrmed that insertion
of an ISAba1-like element in the promoter region
of blaOXA-51-like genes enhances the expression of
such genes, and produces a small increase in the
imipenem MIC.
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